TYBAMATE is a chemical analogue of meprobamate which shares many of the pharmacological properties of the latter drug (Figure). These properties include sedative, anticonvulsant, and musclerelaxant effects. Tybamate differs from meprobamate in that it reverses the electroencephalographic activation produced by lysergic acid diethylamide tartrate (LSD-25) in rabbits, antagonizes the rise in blood pressure induced by serotonin in dogs, and is extensively bound to protein.1 A number of clinical reports, including some double-blind comparisons with placebo and meprobamate, attest to its clinical efficacy.2,3 Despite considerable clinical use, so far no instances of withdrawal reactions have been encountered. Early investigations suggested freedom from withdrawal effects. Even when administered over a long period of time to dogs in doses of 570 mg/kg of body weight; no withdrawal seizures were encountered; dogs treated with comparable doses of meprobamate had frequent withdrawal seizures, often fatal.4
As canine withdrawal reactions have correlated well
Shelton J, Hollister LE. Simulated Abuse of Tybamate in Man: Failure to Demonstrate Withdrawal Reactions. JAMA. 1967;199(5):338–340. doi:10.1001/jama.1967.03120050080022
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: